Juno Therapeutics
Sana Biotechnology is set to start trading on Thursday.
The secretive Seattle-based biotech had raised $705.5 million since it was founded in July 2018.
We dug through its 271-page filing to unearth five key details on the Sana s financials, strategy, and future.
After raising more than $700 million since its 2018 launch, one of the biotech industry s most valuable private companies is set to start trading on Thursday.
Seattle-based Sana Biotechnology filed paperwork on January 14 for an initial public offering. Following a red-hot year for biotech IPOs in 2020, Sana is hoping to take advantage of investor enthusiasm to fuel its ambitious cell and gene therapy programs.
Image by National Institutes of Allergy and Infectious Diseases
UC San Francisco scientists have discovered a new way to control the immune systemâs ânatural killerâ (NK) cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection. The findings could also be used to enhance the ability of cancer immunotherapies to detect and destroy lurking tumors.Â
The study, published Jan. 8, 2021, in the
Journal of Experimental Medicine, addresses a major challenge for the field of regenerative medicine, said lead author Tobias Deuse, MD, the Julien I.E. Hoffman, MD, Endowed Chair in Cardiac Surgery in the UCSF Department of Surgery.Â
Erin Whitney as head of global clinical operations and
Keith White as head of global market access and has also appointed brand strategy consultant
Shauna Horvath to head of global marketing. Whitney joins the team from bluebird bio, while Merck and Genentech veteran White was most recently VP, global market access and pricing at Corbus Pharmaceuticals. Horvath joined Amylyx as a consultant in 2019.
> Culver City, California’s ImmunityBio tapped
Fabio M. Benedetti, M.D., as chief strategy officer, effective Jan. 4. Should ImmunityBio’s NantKwest merger close, Benedetti is expected to assume the role of CSO at the combined company, ImmunityBio said. Benedetti joins from combination therapy specialist Apollomics, where he was chief medical officer.
Sana Biotechnology Announces Appointments to its Board of Directors
Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, join Sana Board of Directors
News provided by
Share this article
Share this article
SEATTLE, Jan. 8, 2021 /PRNewswire/ Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, have been appointed to the Sana Board of Directors. Josh, Alise, and Michelle all share a passion and commitment to our long-term vision of engineering cells to make medicines that improve the lives of patients, said Sana President and CEO Steve Harr. The diversity of their experiences, backgrounds, and expertise will be critical to our strategy, decision-making, risk-management, and governance. I look forward to working with them to continue to build Sana.
BioSpace Announces Top New Life Sciences Companies to Watch in 2021
News provided by
Share this article
Share this article
DES MOINES, Iowa, Jan. 6, 2021 /PRNewswire/ BioSpace, Inc., the leading life sciences news and careers site, has announced their 25 selections for biopharma s most promising up-and-coming companies in 2021.
For the past seven years, BioSpace has been honoring the most innovative new biopharma companies from across the U.S. The
NextGen Bio list has been noted for anticipating organizations on their way to success.
Topping the
NextGen Bio Class of 2021 list is Sana Biotechnology, developer of accessible gene and cell therapy solutions. Having raised $700 million in June, Sana has since acquired Oscine Corp